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he universal gender difference in coronary heart disease
uggests biology rather than environment, and the female
dvantage has long been attributed to a cardioprotective
ffect of estrogen (1). This thesis is now being challenged by
bservational studies of postmenopausal women that failed
o show an association between endogenous estrogen con-
entrations and future cardiovascular risk and by clinical
rials that failed to show that estrogen therapy reduced the
isk of coronary artery disease (2).
An alternate hypothesis for the gender differences is that
estosterone is the bad actor, explaining men’s higher risk of
eart disease. No clinical trials of physiologic testosterone
herapy with clinical heart disease outcomes in men have
een reported, but epidemiologic studies do not support this
hesis either. Cross-sectional studies tend to show higher
evels of estradiol and lower levels of testosterone in men
ith coronary heart disease, and prospective studies show no
ndependent association of circulating sex steroid concen-
rations with subsequent heart disease (3).
In this issue of the Journal, Mäkinen et al. (4) report that
he common carotid intima media thickness (IMT) corre-
ated inversely with serum testosterone and directly with
uteinizing hormone (LH) in middle-aged Finnish men,
ndependent of age, cholesterol, body mass index, blood
ressure, and smoking.
See page 1603
The exposure and outcome variables appear to be well
easured. Blood for hormone assays was obtained after an
vernight fast. Hormone assays were above the level of
ensitivity and showed good interassay coefficients of vari-
tion. However, testosterone was measured only once,
lthough there is considerable day-to-day variation. Carotid
ltrasounds were measured by experienced sonographers
sing a standard protocol. Sonogram readers were unaware
f participants’ clinical details, and there was good between-
isit and between-observer variation. That said, the reader
ight ask: what can we learn about low testosterone and
ardiovascular disease from this paper?
*Editorials published in the Journal of the American College of Cardiology reflect the
iews of the authors and do not necessarily represent the views of JACC or the
merican College of Cardiology.a
From the Department of Family and Preventive Medicine, School of Medicine,
niversity of California, San Diego, La Jolla, California.A first question is: Who are the participants in this study?
en were selected from a population-based cohort—they
ere not patients who complained of andropause symptoms
r were suspected of having cardiovascular disease. Good,
ecause this suggests less bias of ascertainment. Only
opulation-based data can provide an estimate of how
ommon the levels of low testosterone, and its putative
ymptom complex, are in the population. In this Finnish
tudy, unlike previous studies, men were relatively young
mean age, 57 to 58 years) to be expected to have low
estosterone levels. They were selected for having at least
wo of three symptoms thought to be associated with low
estosterone plus either a serum testosterone of9.8 nmol/l
r a LH of6.0 U/l in the presence of normal testosterone,
s a marker for compensated hypogonadal status. Among
he 1,764 men who met the symptom criteria (decreased
trength, decreased libido, and depression in the past five
ears), only 99 had low testosterone or high LH levels and
ere free of known heart disease, hypertension, and diabe-
es. Thus, the first important message is that very few
iddle-aged men with common symptoms that might be
ttributed to testosterone deficiency actually have low tes-
osterone levels.
A second question is: how internally consistent are these
esults? Carotid ultrasound was performed in 96 of the 99
en with andropause symptoms and low testosterone or
igh LH levels. The comparison group was 140 men
elected because they met neither the symptom nor hor-
one criteria. Table 1 of the paper shows that these two
roups differed by male aging symptom score and by
estosterone, as per protocol, but the only other significant
isk factor differences were lower estradiol levels and more
besity in andropausal men. These andropausal men had a
uch greater maximum IMT of the carotid bulb and
ommon carotid than men in the comparison group without
ow testosterone. The common carotid IMT correlated
nversely with serum testosterone (p 0.003) and positively
ith LH (p  0.006).
A third question is: how externally consistent are these
esults? Previous studies have shown that low testosterone is
ssociated with carotid IMT (5–8) and that IMT is a good
arker for current atherosclerosis and future cardiovascular
vents (9,10). However, risk factors that predict atheroscle-
osis may not necessarily be the determinants of clinical
vents. In the case of estrogen therapy for women, it
emains possible that estrogen delays atherosclerosis (11)
ut increases cardiovascular events by inflammation or
hrombosis or some other means (2). Thus, it will be
mportant to assess the cardiovascular safety of testosterone
upplementation in any testosterone treatment trials by
replanned collection of cardiovascular events. Heart disease
s a more common cause of morbidity and mortality than
rostate cancer, despite the greater attention and anxiety
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Editorial Comment May 17, 2005:1609–10The fourth and final question is: what is the mechanism
or this testosterone-IMT association that was independent
f age, cholesterol, body mass index, blood pressure, and
moking? Although the beneficial effects of testosterone in
nimal studies have been shown in one study to be mediated
y an increase in estradiol levels due to aromatization of
estosterone (12), estradiol levels were associated with an-
ropause but not with IMT in the present study. Further-
ore, by what means would LH “with a normal testoster-
ne” be strongly associated with atherosclerosis as estimated
rom carotid IMT?
Sales of testosterone “replacement” therapies to middle-
ged men are increasing rapidly (13). It seems urgent to
nravel the association between andropause symptoms and
estosterone, which co-existed in only 6% of middle-aged
en in this study.
eprint requests and correspondence: Dr. Elizabeth Barrett-
onnor, Department of Family and Preventive Medicine, School of
edicine, University of California, San Diego, 9500 Gilman Drive,
a Jolla, California 92093-0607. E-mail: ebarrettconnor@
csd.edu.
EFERENCES
1. Barrett-Connor E. Sex differences in coronary heart disease. Why are
women so superior? The 1995 Ancel Keys Lecture. Circulation
1997;95:252–64.2. Barrett-Connor E, Grady D, Stefanick ML. The rise and fall of
menopausal hormone therapy. Ann Rev Public Health 2005;26:115–
40.
3. Alexandersen P, Haarbo J, Christiansen C. The relationship of natural
androgens to coronary heart disease in males: a review. Atherosclerosis
1996;125:1–13.
4. Mäkinen J, Järvisalo MJ, Pöllänen P, et al. Increased carotid athero-
sclerosis in andropausal middle-aged men. J Am Coll Cardiol 2005;
45:1603–8.
5. van den Beld AW, Bots ML, Janssen JA, Pols HA, Lamberts SW,
Grobbee DE. Endogenous hormones and carotid atherosclerosis in
elderly men. Am J Epidemiol 2003;157:25–31.
6. Fukui M, Kitagawa Y, Nakamura N, et al. Association between serum
testosterone concentration and carotid atherosclerosis in men with type
2 diabetes. Diabetes Care 2003;26:1869–73.
7. De Pergola G, Pannacciulli N, Ciccone M, Tartagni M, Rizzon P,
Giorgino R. Free testosterone plasma levels are negatively associated
with the intima-media thickness of the common carotid artery in
overweight and obese glucose-tolerant young adult men. Int J Obes
Relat Metab Disord 2003;27:803–7.
8. Muller M, van den Beld AW, Bots ML, Grobbee DE, Lamberts SW,
van der Schouw YT. Endogenous sex hormones and progression of
carotid atherosclerosis in elderly men. Circulation 2004;109:2074–9.
9. Mancini GB, Dahlof B, Diez J. Surrogate markers for cardiovascular
disease: structural markers. Circulation 2004;109:IV22–30.
0. Simon A, Gariepy J, Chironi G, Megnien JL, Levenson J. Intima-
media thickness: a new tool for diagnosis and treatment of cardiovas-
cular risk. J Hypertens 2002;20:159–69.
1. Hodis HN, Mack WJ, Lobo RA, et al. Estrogen in the prevention of
atherosclerosis. A randomized, double-blind, placebo-controlled trial.
Ann Intern Med 2001;135:939–53.
2. Nathan L, Shi W, Dinh H, et al. Testosterone inhibits early
atherogenesis by conversion to estradiol: critical role of aromatase.
Proc Natl Acad Sci USA 2001;98:3589–93.
3. Bhasin S, Buckwalter JG. Testosterone supplementation in older
men: a rational idea whose time has not yet come. J Androl 2001;
22:718 –31.
